Related Experiment Video

Updated: Aug 20, 2025

An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue
10:33

An Enrichment Method for Small Extracellular Vesicles Derived from Liver Cancer Tissue

Published on: February 3, 2023

1.3K

Exosomal circRNAs: A key factor of tumor angiogenesis and therapeutic intervention

Xue-Ping Zhang1, Jun-Peng Pei1, Chun-Dong Zhang1

  • 1Department of Gastrointestinal Surgery, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|November 22, 2022
PubMed

Insights

Circular RNAs (circRNAs) packaged in exosomes regulate tumor angiogenesis. This review explores their functions, mechanisms, and potential as cancer biomarkers and therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumor angiogenesis research has advanced, but drug resistance and limited efficacy persist.
  • Circular RNAs (circRNAs) are newly identified non-coding RNAs involved in intercellular communication.
  • Exosomes facilitate the transport of circRNAs, influencing the tumor microenvironment.

Purpose of the Study:

  • To comprehensively review the role of exosomal circRNAs in regulating angiogenesis.
  • To elucidate the functions and molecular mechanisms of exosomal circRNAs in tumor growth.
  • To explore the potential of exosomal circRNAs as diagnostic biomarkers and therapeutic targets in cancer.

Main Methods:

  • Literature review of preclinical and clinical studies on circRNAs and exosomes.
  • Analysis of molecular mechanisms underlying circRNA-mediated angiogenesis regulation.
  • Examination of technological advancements in exosome engineering for therapeutic applications.

Main Results:

  • Exosomal circRNAs can act as both inducers and inhibitors of angiogenesis.
  • Specific circRNAs are selectively packaged and secreted via exosomes to modulate the tumor microenvironment.
  • Exosomal circRNAs show promise as biomarkers for early cancer detection and prognosis.

Conclusions:

  • Exosomal circRNAs represent a novel class of regulators in tumor angiogenesis.
  • Targeting exosomal circRNAs offers a promising strategy to overcome drug resistance and improve cancer therapy.
  • Advances in exosome-mimetic nanovesicles could enhance the clinical translation of exosomal circRNA therapeutics.
Keywords:
CircRNAExosomal circRNAExosomeTumor angiogenesis

More Related Videos

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.2K
Isolation and Culture Expansion of Tumor-specific Endothelial Cells10:15

Isolation and Culture Expansion of Tumor-specific Endothelial Cells

Published on: October 14, 2015

11.3K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.7K